Quality of life in patients with allergic rhinitis: a clinical trial comparing the use of bilastine versus loratadine

Abstract

Objectives

The aim of this study was to determine whether there were differences in health-related quality of life of patients with allergic rhinitis treated with bilastine 20 mg compared to those treated with loratadine 10 mg.

Design

This was a prospective randomized double-blinded study.

Setting

Otolaryngology outpatient clinics in Criciúma, state of Santa Catarina, Brazil.

Participants

Seventy-three patients, aged between 18 and 63 years, of whom 36 were treated with loratadine 10 mg and 37 with bilastine 20 mg with medication administered once a day for ten days.

Main outcome measures

The outcome was quality of life as assessed by the modified Rhinoconjunctivitis Quality of Life Questionnaire (RQLQm), which was applied at baseline and after 10 days of treatment.

Results

The use of bilastine 20 mg or loratadine 10 mg significantly reduced RQLQm scores after 10 days of treatment (p <0.001); however, there was no statistically significant difference between the two treatment groups (p >0.05).

Conclusions

Health-related quality of life in patients with allergic rhinitis improved significantly after 10 days of treatment with loratadine and bilastine, and the effectiveness of both was equivalent.

This article is protected by copyright. All rights reserved.

from #ORL via xlomafota13 on Inoreader http://ift.tt/29oda7i
via IFTTT